Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells

Neoplasia

Volumn 10, Issue 2, 2008, Pages 99-107

  Vojtěchová, Martina ^a   Turečková, Jolana ^a   Kučerová, Dana ^a   Šloncová, Eva ^a   Vachtenheim, Jiří ^b   Tuháčková, Zdena ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; INITIATION FACTOR 4E BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN AKT1; PROTEIN KINASE B; PROTEIN MTORC1; PROTEIN S6; PROTEIN TYROSINE KINASE; RAPAMYCIN; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; FIBROBLAST; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ROUS SARCOMA ONCOVIRUS; WESTERN BLOTTING;

EID: 39049091952     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07905     Document Type: Article

References (40)

1. Wullschleger S, Loewit R, and Hall MN (2006). TOR signaling in growth and metabolism. Cell 124, 471-484.
2. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, and Sabatini DM (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and RAPTOR-independent pathway that regulates the cytoskeleton. Curr Biol 14, 1296-1302.
3. Fonseca BD, Smith EM, Lee VH, MacKintosh C, and Proud CG (2007). PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 282, 24514-24524.
4. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, and Sabatini DM (2007). PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25, 903-915.
5. Holland EC, Sonenberg N, Pandolfi PP, and Thomas G (2004). Signaling control of mRNA translation in cancer pathogenesis. Oncogene 23, 3138-3144.
6. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, and Avruch J (2005). Rheb binds and regulates the mTOR kinase. Curr Biol 15, 702-713.
7. Tee AR, Manning BD, Roux PP, Cantley LC, and Blenis J (2003). Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13, 1259-1268.
8. Smith EM, Fin SG, Tee AR, Browne GJ, and Proud CG (2005). The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J Biol Chem 280, 18717-18727.
9. Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiquchi K, and Walker CL (2006). Activity of TSC2 is inhibited by Akt-mediated phosphorylation and membrane partitioning. J Cell Biol 173, 279-289.
10. Inoki K and Guan KL (2006). Complexity of the TOR signaling network. Trends Cell Biol 16, 206-212.
11. Roux PP, Ballif BA, Anjum R, Gygi SP, and Blenis J (2004). Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101, 13489-13494.
12. Manning BD and Cantley LC (2007). AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
13. Chen R, Kim O, Yang Y, Sato K, Eisenmann KM, McCarthy J, Chen H, and Qiu Y (2001). Regulation of PKB/Akt activation by tyrosine phosphorylation. J Biol Chem 276, 31858-31862.
14. Jiang T and Qiu Y (2003). Interaction between Src and C-terminal proline-rich motif of Akt is required for Akt activation. J Biol Chem 278, 15789-15793.
15. Conus NM, Hannan KM, Cristiano BE, Hemmings BA, and Pearson RB (2002). Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase. J Biol Chem 277, 38021-38028.
16. Sarbassov DD, Guertin DA, Ali SM, and Sabatini DM (2005). Phosphorylation and regulation of PKB/Akt by the rictor-mTOR complex. Science 307, 1098-1101.
17. Han EK, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T, Giranda VL, and Luo Y (2007). Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 26, 5655-5661.
18. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66, 1500-1508.
19. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, and Khuri FR (2005). Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65, 7052-7058.
20. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, and Sabatini DM (2006). Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 159-168.
21. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Cordon-Cardo C, Pelletier J, and Lowe SW (2004). Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332-337.
22. Vojtěchová M, Šloncová E, Kučerová D, Jiřička J, Sovová V, and Tuháčková Z (2003). Initiation factor eIF2B not p70 S6 kinase is involved in the activation of the PI3-K signaling pathway induced by the v-src oncogene. FEBS Lett 543, 81-86.
23. Vojtěchová M, Šenigl F, Šloncová E, and Tuháčková Z (2006). Regulation of Src activity by the expression of wild-type v-Src and its kinase-dead double Y416F-K295N mutant. Arch Biochem Biophys 455, 136-143.
24. Krieg J, Olivier AR, and Thomas G (1988). Methods in Enzymology: Analysis of 40S Ribosomal Protein S6 Phosphorylation During Mitogenic Response. In Noller HF Jr. and Moldave K. New York: Academic Press, pp. 571-581.
25. Kohn AD, Barthel A, Kovacina KS, Boge A, Wallach B, Summers SA, Birnbaum MJ, Scott PH, Lawrence JC, and Roth RA (1998). Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. J Biol Chem 273, 11937-11943.
26. Turečková J, Wilson EM, Cappalonga JL, and Rotwein P (2001). Insulin-like growth factor-mediated muscle differentiation. J Biol Chem 276, 39264-39270.
27. Karni R, Gus Y, Dor Y, Meyuhas O, and Levitzki A (2005). Active Src elevates the expression of β-catenin by enhancement of cap-dependent translation. Mol Cell Biol 25, 5031-5039.
28. Shah OJ, Kimball SR, and Jefferson LS (2002). The Src-family kinase inhibitor PP1 interferes with the activation of ribosomal protein S6 kinases. Biochem J 366, 57-62.
29. Tuháčková Z, Sovová V, Šloncová E, and Proud CG (1999). Rapamycin-resistant phosphorylation of the initiation factor-4E-binding protein (4E-BP1) in v-Src-transformed hamster fibroblasts. Int J Cancer 81, 963-969.
30. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, and Courtneidge S (2000). SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 20, 9018-9027.
31. Holz MK and Blenis J (2005). Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 280, 26089-26093.
32. Chiang GG and Abraham RT (2005). Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280, 25485-25490.
33. Rebholz H, Panasyuk G, Fenton T, Nemazanyy I, Valovka T, Flajolet M, Ronnstrand L, Stephens L, West A, and Gout IT (2006). Receptor association and tyrosine phosphorylation of S6 kinases. FEBS J 273, 2023-2036.
34. Jin W, Yun C, Hobbie A, Martin MJ, Sorensen PHB, and Kim SJ (2007). Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src. Cancer Res 67, 3192-3200.
35. Deutsch E, Maggiorella L, Wen B, Bonnet ML, Khanfir K, Frascogna V, Turhan AG, and Bourhis J (2004). Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. Br J Cancer 91, 1735-1741.
36. VanderWeele DJ, Zhou R, and Rudin CM (2004). Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther 3, 1605-1613.
37. Puttini M, Coluccia AML, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, et al. (2006). In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl neoplastic cells. Cancer Res 66, 11314-11322.
38. Kim DH, Sarbassov DD, Ali SM, King JE, and Latek RR (2002). mTOR interacts with RAPTOR to form nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175.
39. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, and Sawyers CL (2006). Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12, 122-127.
40. Brugge J, Hung MC, and Mills GB (2007). A new mutational aktivation in the PI3K pathway. Cancer Cell 12, 104-107.